Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 18/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238028 | 0.82 | P2RY2 (0.44) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL3238072 | 0.82 | P2RY2 (0.49) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL3243022 | 0.81 | P2RY2 (0.45) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL3236533 | 0.80 | PNP (0.36) | — | |
| SCHEMBL24414862 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL15810760 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL18609298 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL21277514 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL21277384 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 | |
| SCHEMBL15810759 | 0.76 | P2RY2 (0.51) | P2RY2P2RY4P2RY6P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745417-B2 | Nucleosides or nucleotides having novel unnatural bases and use thereof | RIKEN (JP) | 2010-06-29 | — | — | US | claimed |
| EP-1544294-B1 | NUCLEOSIDES OR NUCLEOTIDES HAVING NOVEL UNNATURAL BASES AND USE THEREOF | RIKEN (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-7960543-B2 | Nucleoside or nucleotide derivative and use thereof | RIKEN (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7745417-B2 | Nucleosides or nucleotides having novel unnatural bases and use thereof | RIKEN (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | RIKEN (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1816130-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVE AND USE THEREOF | Riken (JP) | 2007-08-08 | — | — | EP | disclosed |
| US-20060263771-A1 | Nucleoside or nucleotides having novel unnatural bases and utilization of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-11-23 | — | — | US | disclosed |
| EP-1544294-A1 | NUCLEOSIDES OR NUCLEOTIDES HAVING NOVEL UNNATURAL BASES AND USE THEREOF | Riken (JP) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275017-A1 | Novel Nucleoside or Nucleotide Derivative and Use Thereof | DUT, NT5C3B, NT5C | P2RY2 1018/4885P2RY4 1005/4885P2RY6 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.